Over the last 12 months, Zenas BioPharma insiders reported 16 buys totaling $29.0M and no sales across SEC Form 4 filings.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | MOULDER LEON O JRChief Executive Officer · O·D | ▲ Buy | 60,000 | $17.79 | $1.1M | +3.5% | 2 tranches · indirect |
| Mar 31, 2026 | Lu HongboD | ▲ Buy | 3,768 | $18.63 | $70K | +0.9% | indirect |
| Mar 31, 2026 | Fairmount Funds Management LLCD | ▲ Buy | 150,000 | $20 | $3.0M | +6.8% | indirect |
| Mar 31, 2026 | MOULDER LEON O JRChief Executive Officer · O·D | ▲ Buy | 54,000 | $18.91 | $1.0M | +3.2% | 2 tranches · indirect |
| Mar 31, 2026 | Lu HongboD | ▲ Buy | 75,000 | $20 | $1.5M | +21.6% | indirect |
| Feb 13, 2026 | Allen Patricia LD | ▲ Buy | 19,860 | $25.16 | $500K | — | 4 tranches |
| Feb 11, 2026 | Lu HongboD | ▲ Buy | 25,985 | $22.5 | $585K | +8.1% | indirect |
| Feb 2, 2026 | MOULDER LEON O JRChief Executive Officer · O·D | ▲ Buy | 57,000 | $17.96 | $1.0M | +15.6% | — |
| Jan 9, 2026 | MOULDER LEON O JRChief Executive Officer · O·D | ▲ Buy | 100,000 | $16.39 | $1.6M | +37.6% | 3 tranches |
| Oct 9, 2025 | Nunn Jason RaleighD | ▲ Buy | 63,158 | $19 | $1.2M | +5.7% | indirect |
| Oct 9, 2025 | SR ONE CAPITAL MANAGEMENT, LLC10% | ▲ Buy | 126,315 | $19 | $2.4M | +7.1% | 2 tranches · indirect |
| Oct 9, 2025 | ENRIGHT PATRICK GD | ▲ Buy | 11,990 | $20.85 | $250K | — | — |
| Oct 9, 2025 | ENRIGHT PATRICK GD | ▲ Buy | 105,265 | $19 | $2.0M | +6.1% | indirect |
| Oct 7, 2025 | MOULDER LEON O JRSee Remarks · O·D | ▲ Buy | 36,928 | $20.85 | $770K | — | indirect |
| Oct 7, 2025 | Fairmount Funds Management LLCD | ▲ Buy | 316,219 | $19 | $6.0M | +16.7% | indirect |
| Oct 7, 2025 | Lu HongboD | ▲ Buy | 321,983 | $18.63 | $6.0M | — | 2 tranches · indirect |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Zenas BioPharma filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ZBIO feed.